Long known for its genetic analysis business, San Diego-based Sequenom is hoping to soon cash in on a second endeavor.
The company has been expanding into the arena of molecular diagnostics, working to make noninvasive tests for pregnant women to detect possible disorders in their unborn babies, allowing doctors to begin prenatal treatments when available.
"The market potential is well over a billion dollars in the U.S.," Sequenom's Chief Executive Officer Harry Stylli, Ph.D., said of the molecular diagnostics business.
Press ESC | Close [X]
